Novartis AG (NVS) - Long-Term Debt to Capital

This chart of Novartis AG (NVS) value demonstrates metrics at 0.99. The Swiss behemoth is advancing innovative medicine, leveraging global sales of its patents alongside low production costs. The business relies on breakthrough developments in radioligand and RNA therapies, expanding its presence in the oncology sphere. Simultaneously, the corporation is refreshing its personnel, recruiting biotech experts to support the R&D cycle.

Stable cash flows from the sale of chronic medications at Novartis AG (NVS) allow for the efficient servicing of borrowed funds, as reflected in the long-term debt-to-equity ratio. This coefficient relates liabilities with a maturity of over one year to shareholders' equity, enabling investors to assess the issuer's degree of financial autonomy and the risk of excessive leverage during long-term planning.